Precision oncology released: How innovations in Antibody Drug Conjugate engineering are accelerating the development of smarter cancer therapeutics

The cancer treatment landscape is transforming. Antibody Drug Conjugates (ADCs), known as "biological missiles", are redefining how we target tumors by delivering potent payloads directly to cancer cells while protecting healthy tissue.

In this interview, Simon Scrace from Revvity's Preclinical Services team explores the innovations accelerating ADC development and the screening technologies helping to turn promising concepts into life-saving therapies.

You will learn about:

• How dual-payload ADC designs are overcoming resistance mechanisms
• Approaches to identify novel combinations for ADCs
• Why cell panel screening is critical for identifying synergistic payload combinations
• How functional genomic screening can help uncover ADC processing and resistance mechanisms
• How Revvity's technologies and services support ADC development

Download the article to explore how ADC innovations are reshaping the path to smarter cancer therapeutics.

For research use only. Not for use in diagnostic procedures.